Geode Capital Management’s Sonnet BioTherapeutics SONN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-61,840
| Closed | -$283K | – | 4550 |
|
|
2025
Q3 | $283K | Buy |
61,840
+36,948
| +148% | +$164K | ﹤0.01% | 3816 |
|
|
2025
Q2 | $30.9K | Buy |
24,892
+87
| +0.4% | +$109 | ﹤0.01% | 4298 |
|
|
2025
Q1 | $33.2K | Buy |
+24,805
| New | +$38.1K | ﹤0.01% | 4266 |
|
|
2024
Q3 | – | Sell |
-2,088
| Closed | -$15.7K | – | 4578 |
|
|
2024
Q2 | $15.7K | Buy |
+2,088
| New | +$28.2K | ﹤0.01% | 4492 |
|
|
2023
Q3 | – | Sell |
-962
| Closed | -$83K | – | 4779 |
|
|
2023
Q2 | $83K | Buy |
962
+798
| +487% | +$56.3K | ﹤0.01% | 4390 |
|
|
2023
Q1 | $10.4K | Sell |
164
-3
| -2% | -$486 | ﹤0.01% | 4763 |
|
|
2022
Q4 | $33K | Sell |
167
-128
| -43% | -$28K | ﹤0.01% | 4695 |
|
|
2022
Q3 | $76K | Hold |
295
| – | – | ﹤0.01% | 4672 |
|
|
2022
Q2 | $203K | Buy |
295
+25
| +9% | +$17.9K | ﹤0.01% | 4255 |
|
|
2022
Q1 | $250K | Sell |
270
-187
| -41% | -$158K | ﹤0.01% | 4270 |
|
|
2021
Q4 | $465K | Buy |
457
+255
| +126% | +$366K | ﹤0.01% | 4092 |
|
|
2021
Q3 | $301K | Buy |
202
+196
| +3,267% | +$436K | ﹤0.01% | 4267 |
|
|
2021
Q2 | $24K | Hold |
6
| – | – | ﹤0.01% | 4706 |
|
|
2021
Q1 | $35K | Hold |
6
| – | – | ﹤0.01% | 4426 |
|
|
2020
Q4 | $35K | Buy |
+6
| New | +$38.1K | ﹤0.01% | 4210 |
|
|
2017
Q2 | – | Hold |
0
| – | -$33K | – | 4104 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 4004 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 3951 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 3914 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 3962 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 3900 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 3899 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 3892 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 3747 |
|
Other funds holding SONN
Geode Capital Management's SONN Position: Q4 2025 in Review
Geode Capital Management sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 61,840 shares — an estimated $283K sold.
Geode Capital Management first reported a position in SONN in Q4 2020 and held it in 15 quarters. The position peaked at $465K in Q4 2021. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.
- Geode Capital Management reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
- Geode Capital Management sold 61,840 Sonnet BioTherapeutics shares in Q4 2025, an estimated $283K.
- Geode Capital Management first reported a position in Sonnet BioTherapeutics in Q4 2020 and held it in 15 quarters.
- Geode Capital Management's Sonnet BioTherapeutics position peaked at $465K in Q4 2021.
- 1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.
Based on Geode Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.